We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Pfizer and Myovant Sciences announced Wednesday that the FDA has approved Myfembree,which combines the GnRH antagonist relugolix with hormones estradiol and norethindrone, to manage heavy menstrual bleeding in premenopausal women who have uterine fibroids